Pizzoferato
Caen, 14000, France
Location status: Recruiting
NCT Number: NCT03615872
Genital prolapse is a common pathology with a prevalence ranging from 2.9 to 11.4% or 31.8% to 97.7%, depending on whether a questionnaire or clinical examination is used. The use of pessary in the treatment of prolapse remains discussed despite a satisfaction rate of 50 to 80% in the literature and a minimal complications rate.
The main objective of this study is to assess the satisfaction of patients carrying a pessary in the first year after the laying.
Interested in participating?
Request Info18 year and older
Female
Observational
Caen, 14000, France
Location status: Recruiting
This is a prospective observational cohort conducted at the Universitary hospital of Caen over a total period of 5 years.
Patients with a symptomatic genital prolapse will all be offered the installation of a pessary. If they agree to participate in the study, they will be asked to respond to validated questionnaires: symptom questionnaires (PFDI-20, ICIQ-SF, USP), a sexuality questionnaire (PISQ-12), a quality of life questionnaire (PFIQ-7, BIS) and Satisfaction (PGI-I), several times: Before the installation of the pessary, at one month, at 6 months, then annually over 5 years
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
evaluation of satisfaction of pessary use in case of symptomatic genital prolapse
Time frame: 1 year
The PGI-I score was developed and validated to quantify the effect of urinary incontinence or prolapse treatments
Time frame: 1 to 5 years
The PGI-I score was developed and validated to quantify the effect of urinary incontinence or prolapse treatments
Time frame: at 1 year, then every year for 5 years
This score was developped to evaluate the genital, anorectal and urinary symptoms related to genital prolapse
Time frame: at 1 year, then every year for 5 years
These scores are self-questionnaires specifically validated to evaluate urinary incontinence and urinary tract dysfunctions
Time frame: at 1 year, then every year for 5 years
Evaluation of the PISQ-12 score after the installation of a pessary. This score was developped specifically to evaluate sexual troubles in case of genital prolapse
Time frame: at 1 year, then every year for 5 years
The PFIQ-7 was developped to evaluate the impact of the symptoms on the quality of life
Time frame: 1 year to 5 years
Impact of age (years) on treatment failure (removal or expulsion of pessary)
Time frame: 1 year to 5 years
Impact of menopausal status (yes/no) on treatment failure (removal or expulsion of pessary)
Time frame: 1 year to 5 years
Impact of weight (Kg) on treatment failure (removal or expulsion of pessary)
Time frame: 1 year to 5 years
Impact of hysterectomy history (yes/no) on the removal or expulsion of pessary
Time frame: 1 year to 5 years
Impact of prolapse surgery history (yes/no) on the removal or expulsion of pessary
Time frame: 1 year to 5 years
Impact of the prolapse stage (assessed by the validated POP-Q classification) of on the removal or expulsion of pessary. The stage of prolapse is ranged from 1 to 4 in the POP-Q classification
Time frame: 1 to 5 years
Rate of complications related to the use of a pessary (frequencies)
Contact information is provided by the study sponsor or research team.
Anne Cecile PIZZOFERRATO, MD
CONTACT
Anne VILLOT, MD
CONTACT
University Hospital, Caen
Other
Evaluation of Patient Satisfaction With Pessary in the Treatment of Genital Prolapse
Acronym: PeSaCUP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07066761
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Sankt Johann in Tirol, Tyrol, Austria
View Trial DetailsNCT07306715
Genital Prolapse
Köseköy, Kocaeli, Turkey (Türkiye)
View Trial DetailsNCT06805006
Genital Prolapse, Pathological Conditions, Anatomical
Munich, Bavaria, Germany
View Trial DetailsNCT02585544
Genital Prolapse, Vaginal Floor Prolapse
Bron, France
View Trial Details